The effectiveness of serum S100B, TRAIL and adropin levels in predicting clinical outcome, final infarct core and stroke subtypes of acute ischemic stroke patients

Introduction: To include Objectives: To identify the significance of TRAIL and adropin release and the relative changes related to S100B levels and the relationship between these biomarkers with final infarct core, clinical outcome, and the presence of large artery atherosclerosis in acute stroke patients. Material and methods: Over a one-year period, demographic, clinical, and neuroimaging findings of 90 consecutive patients with acute ischemic stroke were evaluated. Results: Among our study population, the mean age was 69.28 +/- 10 and 39 patients were female. The increased level of S100B and the decreased levels of sTRAIL with adropin were significantly associated with the moderate to the severe patient neurologic presentation (p=.0001, p=.002, p=.002, respectively). On control CT, a large infarct core was significantly associated with decreased serum level of sTRAIL and adropin (p=.001 and p=.000; respectively); however, the levels of S100B were not significantly associated with good ASPECT score (p=.684). Disability and unfavorable outcome were significantly related to the decreased level of sTRAIL and adropin (p=.001 and p=.000; respectively for THRIVE score>5). Decreased sTRAIL and adropin levels and increased S100B level were correlated with the presence of large artery atherosclerotic etiologic factor among the study population (p=.000, p=.000, p=.036, respectively). Conclusion: TRAIL and Adropin serum levels are associated with poor clinical outcome and greater infarcted area in acute ischemic stroke patients.